Dr. Sreekanth Kokkonda

Sreekanth Kokkonda received his Ph.D. degree from Indian Institute of Chemical Technology, Hyderabad, India. In Pradip’s lab, as an Acting Instructor, his research focuses on the design and synthesis of novel chemical entities in drug discovery programs such as hit to lead and lead optimization, SAR studies with the aim of developing novel inhibitors for Plasmodium falciparum enzymes. The current synthetic efforts are directed towards therapeutic targets such as: Plasmodium falciparum DHODH, Acinetobacter baumannii DHODH, Plasmodium falciparum Topoisomerase II. He had contributed significantly to development of the Phase II malaria drug (DSM265) in collaboration with a variety of interdisciplinary groups and the Medicines for Malaria Venture (MMV). Sreekanth has two children.

Email: sreekant@uw.edu

Publications

Kokkonda, S, El Mazouni, F, White, KL, White, J, Shackleford, DM, Lafuente-Monasterio, MJ et al.. Isoxazolopyrimidine-Based Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase with Antimalarial Activity. ACS Omega. 2018;3 (8):9227-9240. doi: 10.1021/acsomega.8b01573. PubMed PMID:30197997 PubMed Central PMC6120730.

Phillips, MA, White, KL, Kokkonda, S, Deng, X, White, J, El Mazouni, F et al.. A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria. ACS Infect Dis. 2016;2 (12):945-957. doi: 10.1021/acsinfecdis.6b00144. PubMed PMID:27641613 PubMed Central PMC5148661.

Kokkonda, S, Deng, X, White, KL, Coteron, JM, Marco, M, de Las Heras, L et al.. Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity. J. Med. Chem. 2016;59 (11):5416-31. doi: 10.1021/acs.jmedchem.6b00275. PubMed PMID:27127993 PubMed Central PMC4904246.

Mudeppa, DG, Kumar, S, Kokkonda, S, White, J, Rathod, PK. Topoisomerase II from Human Malaria Parasites: EXPRESSION, PURIFICATION, AND SELECTIVE INHIBITION. J. Biol. Chem. 2015;290 (33):20313-24. doi: 10.1074/jbc.M115.639039. PubMed PMID:26055707 PubMed Central PMC4536438.

Deng, X, Kokkonda, S, El Mazouni, F, White, J, Burrows, JN, Kaminsky, W et al.. Fluorine modulates species selectivity in the triazolopyrimidine class of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors. J. Med. Chem. 2014;57 (12):5381-94. doi: 10.1021/jm500481t. PubMed PMID:24801997 PubMed Central PMC4079327.

Marwaha, A, White, J, El Mazouni, F, Creason, SA, Kokkonda, S, Buckner, FS et al.. Bioisosteric transformations and permutations in the triazolopyrimidine scaffold to identify the minimum pharmacophore required for inhibitory activity against Plasmodium falciparum dihydroorotate dehydrogenase. J. Med. Chem. 2012;55 (17):7425-36. doi: 10.1021/jm300351w. PubMed PMID:22877245 PubMed Central PMC3446820.